Sharon Fekrat, MD, FASRS

Panelists discuss how faricimab and aflibercept 8 mg compare in drying and durability and how clinicians manage IOP considerations tied to injection frequency, volume, and syringe variability.

Panelists discuss how real-world adherence to loading doses and thoughtful switching or reloading strategies can optimize durability and outcomes, particularly in undertreated patients.

Panelists discuss how the 8-mg aflibercept formulation improves drying efficacy, extends dosing intervals, and reduces burden while maintaining familiarity for patients across AMD and DME.

Panelists discuss how higher-dose and dual-pathway anti-VEGF agents enable longer intervals, improved fluid control, and more flexible treatment strategies across retinal vascular diseases.

Panelists discuss how faricimab’s dual VEGF-A and Ang-2 inhibition may offer vascular stability advantages over single-pathway blockade, despite ongoing questions about Ang-2’s independent therapeutic impact.

Panelists discuss how aflibercept’s structural design and the higher molar dose of its 8-mg formulation enhance VEGF binding, treatment durability, and clinical predictability.

Dr. Sharon Fekrat presented a retrospective analysis assessing how antiplatelet and anticoagulant therapy relates to hemorrhage characteristics and outcomes.

Sharon Fekrat discusses the complexities of antithrombotic use in wet AMD, highlighting the need for individualized treatment and future guideline development.

Panelists discuss how key biologic and clinical distinctions—such as ischemia, leakage patterns, and modality-specific insights—guide tailored treatment strategies for BRVO, CRVO, and DME.

Panelists discuss how differing disease mechanisms, inflammatory drivers, and clinical priorities across AMD, DME, and RVO shape individualized therapeutic goals and the use of newer anti-VEGF agents.

Sharon Fekrat, MD, FACS, FASRS, shares insights on the retinal manifestations of antipsychotic medications.